Monocytes in type 1 diabetes and kidney disease study
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at immune cells (monocytes) in people with type 1 diabetes, with or without early kidney problems. Researchers want to understand how these cells differ between groups. You may be able to join if you have type 1 diabetes and use an insulin pump or injections along with a continuous glucose monitor (CGM).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have been diagnosed with type 1 diabetes
- You use insulin injections or an insulin pump
- You use a continuous glucose monitor (CGM)
- You have either early kidney disease or normal kidney function
- You are not currently using certain diabetes medications like GLP-1 agonists, DPP4 inhibitors, or SGLT2 inhibitors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell injection (CNK-UT009) for adults with type 1 diabetes. The goal is to see if it can help manage blood sugar and reduce insulin needs.
This study tests new treatments to protect the heart and kidneys in people with long-standing type 1 diabetes. It aims to prevent or slow down complications like heart failure and kidney damage.
This study looks at how well “good cholesterol” (HDL) works in people with type 1 diabetes, especially when kidney tests show early or more advanced damage. Researchers will compare different groups (normal, micro-, and macro-albumin in urine) to better understand HDL’s role and how it may relate to kidney health.
This study looks at how people with type 1 diabetes are treated and how their metabolism is doing. It will help doctors understand the condition better and improve care.
This study tests a new sensor that continuously measures ketone levels in people with type 1 diabetes who are also taking SGLT2 inhibitors. It aims to see if the sensor can help prevent diabetic ketoacidosis.
This study tests a new experimental medication for people with type 1 diabetes who experience dangerous low blood sugar episodes and have early-stage kidney disease. The trial aims to help improve blood sugar control and reduce these risky episodes.
Hear when a new Chronic Kidney Disease(CKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.